HIV/TB Research meeting in conjunction with the 20th conference on retroviruses and opportunistic infections (CROI 2013), Sunday 3 March, 2013, 11:30-13:30 Omni Hotel at CNN Center, 100 CNN Center, Atlanta, Georgia, USA Organized by the World Health Organization and CREATE on behalf of the TB/HIV Working Group of the Stop TB Partnership
HIV/TB Research meeting in conjunction with the 20th conference on retroviruses and opportunistic infections (CROI 2013),
Sunday 3 March, 2013, 11:30-13:30
Omni Hotel at CNN Center, 100 CNN Center,
Atlanta, Georgia, USA
Organized by the World Health Organization and CREATE on behalf of the TB/HIV Working Group of the Stop TB Partnership
A third of all people living with HIV worldwide are latently infected with Mycobacteria tuberculosis, making them 21-34 times more likely to develop active TB disease than people who are HIV negative. Despite being preventable and curable, TB is still a leading killer of people living with HIV, with a quarter of all HIV deaths found to be TB-related. This meeting will share data from on-going studies, discuss controversial issues and identify critical research questions. Areas of focus will be on the impact of Isoniazid Preventive Therapy among infants and children living with HIV, rifapentine for TB prevention among people living with HIV, as well as drug interactions of new ART and TB drugs. Please see the provisional agenda of the meeting below.
The meeting is intended for HIV researchers, implementers and public health policy makers. A light lunch will be served during the meeting. Attendance of the meeting will be by confirmed registration only and on a first come, first serve basis. If you are interested in participating please send an e-mail expressing your interest to firstname.lastname@example.org at your earliest convenience but no later than close of business on February 22, 2013.
Convener: Haileyesus Getahun (Stop TB Department, WHO)
Co-chairs: Diane Havlir, (Chair of the Global TB/HIV Working Group and UCSF, USA) and Richard Chaisson, (Johns Hopkins University, USA)
11:30-11:35: Introduction and objectives of the meeting
Isoniazid preventive therapy for children: impact on mortality and incidence of tuberculosis
Charles Mitchell, University of Miami, Miami, FL, USA
Mark Cotton, University of Stellenbosch, South Africa
Rifapentine to prevent TB among people living with HIV: interim data and pending issues
Timothy Sterling, Vanderbilt University, Nashville, TN, USA
Neil Martinson, PHRU, Chris Hani Baragwanath Hospital, Soweto, South Africa (TBC)
12:45-13:00: Drug interactions with ART and new TB drugs: What do we know?
Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Gary Maartens, University of Cape Town Medical School, South Africa
13:25-13:30: General conclusion and next steps